Key Takeaways: Semaglutide is the active ingredient in both Ozempic and Wegovy, working by mimicking GLP-1 to reduce appetite and improve blood sugar control. Wegovy (higher-dose semaglutide) is FDA-approved for weight loss, while Ozempic is primarily approved for type 2 diabetes but often used off-label. Clinical trials show semaglutide can lead to ~15% body weight loss over ~68 weeks when combined with lifestyle changes. Ozempic typically produces slightly lower average weight loss due to its lower maximum dose, though results can still be significant. Gradual tapering off semaglutide, combined with lifestyle support, may help reduce weight regain after stopping treatment. Long-term success depends on pairing medication with nutrition, physical activity, and ongoing medical guidance. Understanding the Basics Semaglutide is the active drug found in both Ozempic and Wegovy

Researchers found that college rugby players taking creatine for three weeks showed a 56% increase in DHT (dihydrotestosterone) levels during the loading phase, with levels remaining 40% above baseline during maintenance
One Indian company was offering generics for as little as $19 CAD a month, and analysts expect around 50 generics could enter the Indian market within months [Source: cbc.ca/news/health/generic-ozempic-canada-waiting-9.7142339]
What Causes Restless Legs Syndrome
Studies demonstrate that satiety levels become more consistent after five weeks
Peptides work synergistically with proper nutrition, exercise, sleep, and stress managementnot as replacements for these fundamentals